SCYNEXIS (SCYX) Director Steven Burke Receives RSU and Derivative Awards

What Happened

• Steven Burke, a director of SCYNEXIS, received two awards on September 18, 2026: 5,750 restricted stock units (RSUs) and 5,750 additional derivative awards. Both grants were reported at a $0.00 acquisition price (typical for compensation awards). Total award count: 11,500 units.

Key Details

• Transaction date: September 18, 2026; Form 4 filed September 22, 2026.
• Grant price: $0.00 for both awards (no cash paid).
• Shares reported: 5,750 RSUs (per footnote F1) and 5,750 derivative awards (per footnote F2) — total 11,500 units granted.
• Vesting (per footnotes):
  • F1 (RSUs): Each RSU converts to one share at vesting; 1/3 of these RSUs vest annually, first vesting on Sept 18, 2027, subject to continued service.
  • F2 (derivative award / option-style vesting): 1/3 vests on the one-year anniversary, then 1/36 vests each month for the next 24 months, subject to continued service.
• Shares owned after the transaction: not specified in the provided filing.
• Filing timeliness: Form filed 4 days after the transaction (Sept 22); this appears to be within the SEC’s 2-business-day reporting window for Form 4s when accounting for the weekend.

Context

• These are compensation grants, not open-market purchases or sales. RSUs convert to common shares only as they vest; the derivative award follows an option-style vesting schedule and would only result in shares if vested and exercised according to plan terms.
• Compensation grants are routine for executives/directors and reflect company pay practices rather than direct buy/sell market signals.